Home
ALGS
ALGS News

Latest Aligos Therapeutics Inc. (ALGS) News on November 25, 2025

Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

11 days ago

Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Aligos Therapeutics Presents Positive Data at The Liver Meeting® 2025

GlobeNewswire

15 days ago

Aligos Therapeutics Presents Positive Data at The Liver Meeting® 2025

Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2025 Financial Results

GlobeNewswire

19 days ago

Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2025 Financial Results

Aligos Therapeutics to Present at Upcoming Investor Conferences

GlobeNewswire

21 days ago

Aligos Therapeutics to Present at Upcoming Investor Conferences

Aligos Therapeutics to Announce 3rd Quarter 2025 Financial Results on November 6, 2025

GlobeNewswire

a month ago

Aligos Therapeutics to Announce 3rd Quarter 2025 Financial Results on November 6, 2025

Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

a month ago

Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Aligos Therapeutics Receives USAN Council Approval for pevifoscorvir sodium as Nonproprietary Name for ALG-000184

GlobeNewswire

a month ago

Aligos Therapeutics Receives USAN Council Approval for pevifoscorvir sodium as Nonproprietary Name for ALG-000184

Aligos Therapeutics to Present at the H.C. Wainwright Liver Disease Conference

GlobeNewswire

a month ago

Aligos Therapeutics to Present at the H.C. Wainwright Liver Disease Conference

Aligos Therapeutics Announces Eight Abstracts Accepted at The Liver Meeting® 2025

GlobeNewswire

2 months ago

Aligos Therapeutics Announces Eight Abstracts Accepted at The Liver Meeting® 2025

Does Aligos Therapeutics (ALGS) Have the Potential to Rally 737.74% as Wall Street Analysts Expect?

Zacks

3 months ago

Does Aligos Therapeutics (ALGS) Have the Potential to Rally 737.74% as Wall Street Analysts Expect?

Aligos Therapeutics Appoints Kieron Wesson as Vice President, Head of Chemistry Manufacturing Controls (CMC)

GlobeNewswire

5 months ago

Aligos Therapeutics Appoints Kieron Wesson as Vice President, Head of Chemistry Manufacturing Controls (CMC)

Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

5 months ago

Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Aligos Therapeutics to Present at the Jefferies Global Healthcare Conference

GlobeNewswire

6 months ago

Aligos Therapeutics to Present at the Jefferies Global Healthcare Conference

Aligos Therapeutics Appoints Laura Kavanaugh as Vice President, Head of Legal

GlobeNewswire

6 months ago

Aligos Therapeutics Appoints Laura Kavanaugh as Vice President, Head of Legal

Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

6 months ago

Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Aligos Therapeutics First Quarter 2025 Earnings: Revenues Miss Expectations

Simply Wall St.

6 months ago

Aligos Therapeutics First Quarter 2025 Earnings: Revenues Miss Expectations

Aligos Therapeutics Presents Positive Data at the EASL Congress 2025

GlobeNewswire

7 months ago

Aligos Therapeutics Presents Positive Data at the EASL Congress 2025

Aligos Therapeutics, Inc. (ALGS) Reports Q1 Loss, Misses Revenue Estimates

Zacks

7 months ago

Aligos Therapeutics, Inc. (ALGS) Reports Q1 Loss, Misses Revenue Estimates

Aligos Therapeutics Reports Recent Business Progress and First Quarter 2025 Financial Results

GlobeNewswire

7 months ago

Aligos Therapeutics Reports Recent Business Progress and First Quarter 2025 Financial Results

UPS downgraded, ServiceNow upgraded: Wall Street's top analyst calls

The Fly

7 months ago

UPS downgraded, ServiceNow upgraded: Wall Street's top analyst calls

Aligos Therapeutics to Announce 1st Quarter 2025 Financial Results on May 6, 2025

GlobeNewswire

7 months ago

Aligos Therapeutics to Announce 1st Quarter 2025 Financial Results on May 6, 2025

Aligos Therapeutics Announces Eight Abstracts Accepted for Presentation at the EASL Congress 2025

GlobeNewswire

7 months ago

Aligos Therapeutics Announces Eight Abstracts Accepted for Presentation at the EASL Congress 2025

Aligos Therapeutics Presents Positive Data at APASL 2025

GlobeNewswire

8 months ago

Aligos Therapeutics Presents Positive Data at APASL 2025

Biotech Alert: Searches spiking for these stocks today

TipRanks

8 months ago

Biotech Alert: Searches spiking for these stocks today

Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

8 months ago

Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Aligos Therapeutics, Inc. (ALGS) Reports Q4 Loss, Lags Revenue Estimates

Zacks

9 months ago

Aligos Therapeutics, Inc. (ALGS) Reports Q4 Loss, Lags Revenue Estimates

Aligos Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2024 Financial Results

GlobeNewswire

9 months ago

Aligos Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2024 Financial Results

Aligos Therapeutics to Announce 4th Quarter 2024 Financial Results on March 10, 2025

GlobeNewswire

9 months ago

Aligos Therapeutics to Announce 4th Quarter 2024 Financial Results on March 10, 2025

Aligos Therapeutics Announces $105 Million Private Placement Financing

GlobeNewswire

9 months ago

Aligos Therapeutics Announces $105 Million Private Placement Financing

Here's Why Aligos Therapeutics (NASDAQ:ALGS) Must Use Its Cash Wisely

Simply Wall St.

10 months ago

Here's Why Aligos Therapeutics (NASDAQ:ALGS) Must Use Its Cash Wisely

PTC Therapeutics (PTCT) Moves 9.0% Higher: Will This Strength Last?

Zacks

10 months ago

PTC Therapeutics (PTCT) Moves 9.0% Higher: Will This Strength Last?

Here’s Why Aligos Therapeutics, Inc. (ALGS) Is Skyrocketing

Insider Monkey

10 months ago

Here’s Why Aligos Therapeutics, Inc. (ALGS) Is Skyrocketing

Aligos Therapeutics, Inc.'s (NASDAQ:ALGS) biggest owners are retail investors who got richer after stock soared 17% last week

Simply Wall St.

a year ago

Aligos Therapeutics, Inc.'s (NASDAQ:ALGS) biggest owners are retail investors who got richer after stock soared 17% last week

Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

a year ago

Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Aligos Therapeutics to Present at Investor Conferences in December

GlobeNewswire

a year ago

Aligos Therapeutics to Present at Investor Conferences in December

Aligos Therapeutics Presents Positive Data at The Liver Meeting (TLM) 2024

GlobeNewswire

a year ago

Aligos Therapeutics Presents Positive Data at The Liver Meeting (TLM) 2024

Aligos Therapeutics Third Quarter 2024 Earnings: Revenues Beat Expectations

Simply Wall St.

a year ago

Aligos Therapeutics Third Quarter 2024 Earnings: Revenues Beat Expectations

Aligos Therapeutics, Inc. (ALGS) Reports Q3 Loss, Tops Revenue Estimates

Zacks

a year ago

Aligos Therapeutics, Inc. (ALGS) Reports Q3 Loss, Tops Revenue Estimates

Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2024 Financial Results

GlobeNewswire

a year ago

Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2024 Financial Results

Aligos Therapeutics to Announce 3rd Quarter 2024 Financial Results on November 6, 2024

GlobeNewswire

a year ago

Aligos Therapeutics to Announce 3rd Quarter 2024 Financial Results on November 6, 2024

Aligos Therapeutics Announces U.S. FDA Clearance of IND Application for ALG-000184

GlobeNewswire

a year ago

Aligos Therapeutics Announces U.S. FDA Clearance of IND Application for ALG-000184

Aligos Therapeutics Announces Acceptance of Abstracts on Incremental Data from ALG-000184 in CHB Subjects and Late-Breaker Oral Presentation of Data from the Phase 2a HERALD Study of ALG-055009 in MASH Subjects at The Liver Meeting (TLM) 2024

GlobeNewswire

a year ago

Aligos Therapeutics Announces Acceptance of Abstracts on Incremental Data from ALG-000184 in CHB Subjects and Late-Breaker Oral Presentation of Data from the Phase 2a HERALD Study of ALG-055009 in MASH Subjects at The Liver Meeting (TLM) 2024

Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

a year ago

Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Aligos Therapeutics Appoints David Perry as Vice President of Business Development

GlobeNewswire

a year ago

Aligos Therapeutics Appoints David Perry as Vice President of Business Development

Aligos Therapeutics to Present at Investor Conferences in October

GlobeNewswire

a year ago

Aligos Therapeutics to Present at Investor Conferences in October

Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of Hardean Achneck, MD as Chief Medical Officer

GlobeNewswire

a year ago

Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of Hardean Achneck, MD as Chief Medical Officer

Aligos reports positive data from Phase IIa MASH treatment trial

Clinical Trials Arena

a year ago

Aligos reports positive data from Phase IIa MASH treatment trial

Aligos Therapeutics Announces Positive Topline Results from the Phase 2a HERALD Study of ALG-055009 for the Treatment of MASH

GlobeNewswire

a year ago

Aligos Therapeutics Announces Positive Topline Results from the Phase 2a HERALD Study of ALG-055009 for the Treatment of MASH

Aligos Therapeutics to Announce Topline Results from the Phase 2a HERALD Study of ALG-055009 for the Treatment of MASH on September 19, 2024

GlobeNewswire

a year ago

Aligos Therapeutics to Announce Topline Results from the Phase 2a HERALD Study of ALG-055009 for the Treatment of MASH on September 19, 2024

Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

a year ago

Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Zacks

a year ago

Are Medical Stocks Lagging Aligos Therapeutics (ALGS) This Year?

How Much Upside is Left in Aligos Therapeutics (ALGS)? Wall Street Analysts Think 648.14%

Zacks

a year ago

How Much Upside is Left in Aligos Therapeutics (ALGS)? Wall Street Analysts Think 648.14%

MT Newswires

a year ago

Aligos Therapeutics to Implement 1-for-25 Reverse Stock Split; Shares Fall

Aligos Therapeutics Announces Reverse Stock Split

GlobeNewswire

a year ago

Aligos Therapeutics Announces Reverse Stock Split

What Makes Aligos Therapeutics (ALGS) a New Buy Stock

Zacks

a year ago

What Makes Aligos Therapeutics (ALGS) a New Buy Stock

Aligos Therapeutics Strengthens Board with Two New Independent Directors

GlobeNewswire

a year ago

Aligos Therapeutics Strengthens Board with Two New Independent Directors

Aligos Therapeutics Second Quarter 2024 Earnings: EPS: US$0.032 (vs US$0.43 loss in 2Q 2023)

Simply Wall St.

a year ago

Aligos Therapeutics Second Quarter 2024 Earnings: EPS: US$0.032 (vs US$0.43 loss in 2Q 2023)

Hepatitis B market is ripe for treatment development, says Aligos CEO

Pharmaceutical Technology

a year ago

Hepatitis B market is ripe for treatment development, says Aligos CEO

Aligos Therapeutics Reports Recent Business Progress and Second Quarter 2024 Financial Results

GlobeNewswire

a year ago

Aligos Therapeutics Reports Recent Business Progress and Second Quarter 2024 Financial Results

Aligos Therapeutics to Announce 2nd Quarter 2024 Financial Results on August 6, 2024

GlobeNewswire

a year ago

Aligos Therapeutics to Announce 2nd Quarter 2024 Financial Results on August 6, 2024

Companies Like Aligos Therapeutics (NASDAQ:ALGS) Could Be Quite Risky

Simply Wall St.

a year ago

Companies Like Aligos Therapeutics (NASDAQ:ALGS) Could Be Quite Risky

MT Newswires

a year ago

Aligos Therapeutics Collaborating With Xiamen Amoytop Biotech in China for Chronic Hepatitis B Patients

Aligos Therapeutics Announces Clinical Collaboration with Xiamen Amoytop Biotech Co., Ltd.

GlobeNewswire

a year ago

Aligos Therapeutics Announces Clinical Collaboration with Xiamen Amoytop Biotech Co., Ltd.

Aligos Therapeutics to Host KOL Event to Discuss the Positive Phase 1b Data from ALG-000184 for the Treatment of CHB

GlobeNewswire

a year ago

Aligos Therapeutics to Host KOL Event to Discuss the Positive Phase 1b Data from ALG-000184 for the Treatment of CHB

AbbVie (ABBV) Parkinson's Candidate Faces 2nd FDA Rejection

Zacks

a year ago

AbbVie (ABBV) Parkinson's Candidate Faces 2nd FDA Rejection

GSK's Filing for Expanded Use of Jemperli Gets EMA Acceptance

Zacks

a year ago

GSK's Filing for Expanded Use of Jemperli Gets EMA Acceptance

J&J (JNJ) Seeks Expanded Use of Tremfya for Crohn's Disease

Zacks

a year ago

J&J (JNJ) Seeks Expanded Use of Tremfya for Crohn's Disease

AstraZeneca's (AZN) Truqap Gets EU Nod for Breast Cancer

Zacks

a year ago

AstraZeneca's (AZN) Truqap Gets EU Nod for Breast Cancer

Zentalis (ZNTL) Tanks After FDA Puts 3 Cancer Studies on Hold

Zacks

a year ago

Zentalis (ZNTL) Tanks After FDA Puts 3 Cancer Studies on Hold

AstraZeneca's (AZN) Truqap Misses Endpoints in TNBC Study

Zacks

a year ago

AstraZeneca's (AZN) Truqap Misses Endpoints in TNBC Study

5 Reasons a Biden Second Term Could Be a Financial Disaster for Boomers

GOBankingRates

a year ago

5 Reasons a Biden Second Term Could Be a Financial Disaster for Boomers

Bumrah delivers as India beat Pakistan in low-scoring thriller

AFP

a year ago

Bumrah delivers as India beat Pakistan in low-scoring thriller

Italy beat Bosnia in final Euros warm-up

AFP

a year ago

Italy beat Bosnia in final Euros warm-up

Macron Calls French Legislative Election After Far-Right Surge

Bloomberg

a year ago

Macron Calls French Legislative Election After Far-Right Surge

Trump loyalists proud to support 'felon' at Las Vegas rally

AFP

a year ago

Trump loyalists proud to support 'felon' at Las Vegas rally

US solar producers could finally have a fighting chance as tariffs kick in on cheaper imports from Asia

Business Insider

a year ago

US solar producers could finally have a fighting chance as tariffs kick in on cheaper imports from Asia

The Best Woody Perfume For Women

Insider Monkey

a year ago

The Best Woody Perfume For Women

Microsoft unveils all-digital Xbox consoles, 'Doom' title at Games Showcase

Reuters

a year ago

Microsoft unveils all-digital Xbox consoles, 'Doom' title at Games Showcase

Aligos Therapeutics Presents Positive Data at the EASL Congress 2024

GlobeNewswire

a year ago

Aligos Therapeutics Presents Positive Data at the EASL Congress 2024

Here's Why Aligos Therapeutics (ALGS) Is a Great 'Buy the Bottom' Stock Now

Zacks

a year ago

Here's Why Aligos Therapeutics (ALGS) Is a Great 'Buy the Bottom' Stock Now

Aligos Therapeutics Announces Six Abstracts Accepted for Presentation at EASL 2024

GlobeNewswire

2 years ago

Aligos Therapeutics Announces Six Abstracts Accepted for Presentation at EASL 2024

Aligos Therapeutics Announces the Completion of Enrollment in the ALG-055009 Phase 2a HERALD Study for the Treatment of MASH

GlobeNewswire

2 years ago

Aligos Therapeutics Announces the Completion of Enrollment in the ALG-055009 Phase 2a HERALD Study for the Treatment of MASH

After Plunging -13.71% in 4 Weeks, Here's Why the Trend Might Reverse for Aligos Therapeutics (ALGS)

Zacks

2 years ago

After Plunging -13.71% in 4 Weeks, Here's Why the Trend Might Reverse for Aligos Therapeutics (ALGS)

Aligos Therapeutics First Quarter 2024 Earnings: US$0.22 loss per share (vs US$0.54 loss in 1Q 2023)

Simply Wall St.

2 years ago

Aligos Therapeutics First Quarter 2024 Earnings: US$0.22 loss per share (vs US$0.54 loss in 1Q 2023)

Aligos Therapeutics Reports Recent Business Progress and First Quarter 2024 Financial Results

GlobeNewswire

2 years ago

Aligos Therapeutics Reports Recent Business Progress and First Quarter 2024 Financial Results

Aligos Therapeutics to Announce 1st Quarter 2024 Financial Results on May 7, 2024

GlobeNewswire

2 years ago

Aligos Therapeutics to Announce 1st Quarter 2024 Financial Results on May 7, 2024

Aligos Therapeutics Presents Positive Clinical Data at ESCMID 2024 from the ALG-097558 Phase 1 Study

GlobeNewswire

2 years ago

Aligos Therapeutics Presents Positive Clinical Data at ESCMID 2024 from the ALG-097558 Phase 1 Study

Aligos Therapeutics Mourns the Passing of MASH Industry Leader Stephen A. Harrison, MD

GlobeNewswire

2 years ago

Aligos Therapeutics Mourns the Passing of MASH Industry Leader Stephen A. Harrison, MD

Aligos Therapeutics to Participate in the Piper Sandler Spring Biopharma Symposium 2024

GlobeNewswire

2 years ago

Aligos Therapeutics to Participate in the Piper Sandler Spring Biopharma Symposium 2024

Aligos Therapeutics Announces First Subjects Dosed in the Phase 2a HERALD Study of ALG-055009 in MASH Subjects

GlobeNewswire

2 years ago

Aligos Therapeutics Announces First Subjects Dosed in the Phase 2a HERALD Study of ALG-055009 in MASH Subjects

Aligos Therapeutics, Inc. (ALGS) Just Flashed Golden Cross Signal: Do You Buy?

Zacks

2 years ago

Aligos Therapeutics, Inc. (ALGS) Just Flashed Golden Cross Signal: Do You Buy?

Aligos Therapeutics Presents Positive Clinical Data at APASL 2024 from ALG-055009 and ALG-000184 Phase 1 Studies

GlobeNewswire

2 years ago

Aligos Therapeutics Presents Positive Clinical Data at APASL 2024 from ALG-055009 and ALG-000184 Phase 1 Studies

Aligos Therapeutics Announces the Initiation of the Phase 2a HERALD Study of ALG-055009 in MASH Subjects

GlobeNewswire

2 years ago

Aligos Therapeutics Announces the Initiation of the Phase 2a HERALD Study of ALG-055009 in MASH Subjects

Aligos Therapeutics Full Year 2023 Earnings: EPS Beats Expectations, Revenues Lag

Simply Wall St.

2 years ago

Aligos Therapeutics Full Year 2023 Earnings: EPS Beats Expectations, Revenues Lag

Aligos Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2023 Financial Results

GlobeNewswire

2 years ago

Aligos Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2023 Financial Results

Aligos Therapeutics to Announce 4th Quarter 2023 Financial Results on March 12, 2024

GlobeNewswire

2 years ago

Aligos Therapeutics to Announce 4th Quarter 2023 Financial Results on March 12, 2024

Aligos Therapeutics To Participate in the Leerink Partners Global Biopharma Conference 2024

GlobeNewswire

2 years ago

Aligos Therapeutics To Participate in the Leerink Partners Global Biopharma Conference 2024

Aligos Therapeutics to Host KOL Event to Discuss Phase 2a HERALD Study of ALG-055009 in MASH on March 7, 2024

GlobeNewswire

2 years ago

Aligos Therapeutics to Host KOL Event to Discuss Phase 2a HERALD Study of ALG-055009 in MASH on March 7, 2024

Aligos Therapeutics Strengthens Finance Leadership Team with Two New Appointments

GlobeNewswire

2 years ago

Aligos Therapeutics Strengthens Finance Leadership Team with Two New Appointments

After losing 41% in the past year, Neuronetics, Inc. (NASDAQ:STIM) institutional owners must be relieved by the recent gain

Simply Wall St.

2 years ago

After losing 41% in the past year, Neuronetics, Inc. (NASDAQ:STIM) institutional owners must be relieved by the recent gain

Share on Social Networks: